Monashee Investment Management LLC Acquires Shares of 40,000 LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Monashee Investment Management LLC purchased a new position in LeMaitre Vascular, Inc. (NASDAQ:LMAT) during the fourth quarter, Holdings Channel.com reports. The institutional investor purchased 40,000 shares of the medical instruments supplier’s stock, valued at approximately $3,686,000. LeMaitre Vascular comprises about 0.5% of Monashee Investment Management LLC’s portfolio, making the stock its 18th largest position.

A number of other large investors have also modified their holdings of the business. Northern Trust Corp boosted its stake in LeMaitre Vascular by 5.1% during the fourth quarter. Northern Trust Corp now owns 327,815 shares of the medical instruments supplier’s stock worth $30,205,000 after buying an additional 15,843 shares during the last quarter. Tudor Investment Corp ET AL lifted its stake in LeMaitre Vascular by 111.8% during the 4th quarter. Tudor Investment Corp ET AL now owns 39,012 shares of the medical instruments supplier’s stock worth $3,595,000 after acquiring an additional 20,597 shares in the last quarter. Susquehanna Fundamental Investments LLC purchased a new position in shares of LeMaitre Vascular in the fourth quarter valued at approximately $351,000. Nebula Research & Development LLC grew its stake in shares of LeMaitre Vascular by 159.5% in the fourth quarter. Nebula Research & Development LLC now owns 8,469 shares of the medical instruments supplier’s stock worth $780,000 after acquiring an additional 5,206 shares in the last quarter. Finally, Oberweis Asset Management Inc. grew its stake in LeMaitre Vascular by 1.6% during the 4th quarter. Oberweis Asset Management Inc. now owns 102,305 shares of the medical instruments supplier’s stock worth $9,426,000 after purchasing an additional 1,601 shares in the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

Analyst Ratings Changes

LMAT has been the topic of a number of recent analyst reports. Barrington Research downgraded shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday, February 28th. Lake Street Capital increased their price target on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the stock a “buy” rating in a research note on Friday, February 28th. Wells Fargo & Company started coverage on shares of LeMaitre Vascular in a research note on Thursday, February 13th. They set an “equal weight” rating and a $95.00 price target on the stock. Finally, Oppenheimer downgraded LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday, February 28th. Five investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, LeMaitre Vascular currently has an average rating of “Moderate Buy” and a consensus price target of $98.14.

Insider Transactions at LeMaitre Vascular

In other LeMaitre Vascular news, insider Trent G. Kamke sold 2,009 shares of the firm’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total value of $164,979.08. Following the transaction, the insider now directly owns 5,564 shares of the company’s stock, valued at $456,915.68. This trade represents a 26.53 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 10.79% of the company’s stock.

LeMaitre Vascular Trading Up 1.2 %

Shares of LMAT stock opened at $92.60 on Wednesday. The company has a market capitalization of $2.09 billion, a price-to-earnings ratio of 50.60, a PEG ratio of 2.22 and a beta of 0.89. The firm has a 50-day moving average price of $86.50 and a 200 day moving average price of $93.45. LeMaitre Vascular, Inc. has a twelve month low of $64.44 and a twelve month high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 EPS for the quarter, meeting the consensus estimate of $0.49. The firm had revenue of $55.81 million during the quarter, compared to analyst estimates of $55.99 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. As a group, research analysts predict that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 27th. Investors of record on Thursday, March 13th were given a $0.20 dividend. This is a positive change from LeMaitre Vascular’s previous quarterly dividend of $0.16. This represents a $0.80 annualized dividend and a dividend yield of 0.86%. The ex-dividend date was Thursday, March 13th. LeMaitre Vascular’s dividend payout ratio (DPR) is 41.24%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.